Akums launches generic formulation to treat migraine
时间:2024-06-26 17:11:01 阅读(143)
Akums Drugs & Pharmaceuticals Ltd., a contract manufacturing pharmaceutical company, on Friday announced that it has launched the Lasmiditan tablet which is prescribed to treat migraine. This medication has received approvals from the Drug Controller General of India (DCGI) and the United States Food and Drug Administration (USFDA).
It is the generic formulation of Eli Lilly’s REYVOW which is indicated for treatment of acute migraine.
In a 2019 report, it was revealed that headache disorders, including both migraines and tension-type headaches, have emerged as the most prevalent neurological conditions in India, affecting an astonishing 488 million individuals.
The International Headache Society (IHS) outlines criteria for diagnosing migraine, including specific characteristics and associated symptoms observed in at least five attacks. Two main subtypes, migraine without aura and migraine with aura, present distinct features, with the latter involving focal neurological symptoms preceding or accompanying the headache.
“Migraine poses a significant global impact. According to a 2019 report, headache disorders, encompassing migraine and tension-type headaches, emerged as the most widespread neurological conditions in India, impacting a staggering 488 million individuals. Despite this substantial prevalence and the resulting disability, migraine awareness among patients remains inadequate. Compounded by frequent misdiagnosis as other headache disorders, these factors contribute to an increased burden associated with migraine. In light of this, Akums aims to provide a solution for managing this condition with the introduction of the Lasmiditan tablet,” Sanjeev Jain, Joint Managing Director, Akums Drugs & Pharmaceuticals Ltd., said.
猜你喜欢
- Sensex ends in red, Nifty above 17150 support may hit 17450; rising crude prices, falling rupee hit sentiment
- Christmas Gifting Ideas- 23 thoughtful gifts for your loved ones
- Rating- buy; Bajaj Auto – Exports to pick up in FY25
- Rating- HOLD; RBL Bank- Aggressive retail growth plans
- California wildfire- Highway Fire burns 25 acres of land, evacuation ordered – Photos
- Buy RIL, ITC stocks ahead of Union Budget 2021, charts tell; watch these key support levels for Nifty
- Rating- attractive; Banks see reversal in loan growth trends
- Rating- buy; Embassy REIT- Stable performance
- Q1 earnings, global cues, FII to influence trading in equities this week- Analysts